NCT05848206View on ClinicalTrials.gov

Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

CompletedOBSERVATIONAL
Enrollment

251,831

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

April 29, 2022

Study Completion Date

April 29, 2022

Conditions
Chronic Heart Failure
Trial Locations (1)

27703

IQVIA, Durham

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT05848206 - Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S. | Biotech Hunter | Biotech Hunter